Study #2022-0264
A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of 177Lu-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR)
MD Anderson Study Status
Not Accepting
Treatment Agent
[177Lu]-NeoB, [68Ga]-NeoB, LCZ696
Description
The purpose of this first-in-human (FIH) study of \[177Lu\]-NeoB is to characterize the safety, tolerability, pharmacokinetics (PK) as well as the distribution and radiation dosimetry, and anti-tumor activity of \[177Lu\]-NeoB in patients with advanced solid tumors known to overexpress Gastrin-Releasing Peptide Receptor (GRPR) and with \[68Ga\]-NeoB lesion uptake.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Neoplasms
Study phase:
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.